消臌软坚丸对肝硬化大鼠血细胞因子及血管活性因子的影响

Effect of Xiaoguruanjian Pill on Blood TNF,IL-1,IL-6,NO and ET-1 of Rats with Liver Cirrhosis

目的:研究消臌软坚丸对肝硬化大鼠模型血清肿瘤坏死因子(TNF)、白细胞介素1、6(IL-1、IL-6)、一氧化氮及其合酶(NO、NOS)及血浆内皮素1(ET-1)的调控作用。方法:采用四氯化碳为主的复合因素造模法复制肝硬化大鼠模型,分为正常组、模型组、消臌软坚丸低剂量组和高剂量组及阳性药对照组(复方鳖甲软肝片),5组均于造模结束后第2天连续灌服0.85％氯化钠液或药物28d后断头取血,分别检测血清TNF、IL-1、IL-6、NO、NOS及ET-1含量。结果:①消臌软坚丸各治疗组TNF、IL-1、IL-6的含量均低于模型组(P<0.01),高剂量组低于对照组(P<0.05或<0.01);低剂量组IL-1、TNF的含量低于对照组(P<0.01),而IL-6的含量与对照组之间差异无统计学意义(P>0.05);高、低剂量组之间差异未见统计学意义(I'>0.05)。②消臌软坚丸各治疗组NO、NOS的含量均低于模型组(P<0.01);高剂量组NO、NOS的含量均低于低剂量组和对照组(P<0.01);低剂量组NOS的含量低于对照组(P<0.01)。③消臌软坚丸各治疗组均能明显降低血浆ET-1的含量(P<0.01)。高、低剂量组ET-1的含量均低于对照组(P<0.01)。高剂量组ET-1的含量低于低剂量组(P<0.01)。结论:①消臌软坚丸可显著下调肝硬化模型大鼠血清异常升高的TNF、IL-1、IL-6的水平;②消臌软坚丸可显著降低肝硬化大鼠血NO?

To study the effect of Xiaoguruanjian pill(XP) on blood TNF、IL-1, IL-6, NO and ET-1 of rats with liver cirrhosis. Methods:Rat models of liver Cirrhosis were made with multiple factors (mainly by injecting CCl_4). Sixty Wistar rats were randomly divided into five groups: normal control group, model control group, low dose XP group, high dose XP group and positive control group(Biejiaruangan Tablet). From the second day after the inducement of the models, all rats were continuously infused with saline or the medicine for 28 days, and were cut off head for obtaining blood after the last medication. The blood was centrifuged and separated for serum and blood plasma in tow temperature. The contents of TNF, IL-1, IL-6, NO and ET-1 were detected separately. Results: 1. After the medication, the contents of serum IL-1, IL-6, TNF in each treatment group were lower than those of model group (P<0.01), the contents of serum IL-1, IL-6, TNF in high-dose XP group were lower than those of control group( P<0.05 or P<0.01),the contents of serum IL-1 and TNF in low-dose XP group were lower than those of control group(P<0.01), and there was no significant difference between high-dose group and low-dose group(P>0.05). 2. After the medication, the contents of serum NO and NOS in each treatment group were lower than those of model group (P<0.01), the contents of serum NO and NOS in high-dose XP group were lower than those of low-dose XP group and control group(P<0.01),the content of serum NOS in low-dose XP group was lower than that of control group(P<0. 01). 3. After the medication, the content of plasma ET-1 in each treatment group was lower than that of model group (P<0.01), the content of plasma ET-1 in high-dose group was lower than that of low-dose XP group and control group(P<0.01). Conclusion. 1. XP can decrease obviously the level of serum TNF, IL-1, IL-6,which abnormally are heightened in rat models of liver cirrhosis. 2. XP can lower the contents of serum NO, NOS of and plasma ET-1, which indicates that this prescription can alleviate inflammation injury, improve system hyperkinetic circulatory state, relieve portal hypertension and liver microcirculation disorder, decrease or restrain the happening or development of ascites.